Valence-Transforming O<sub>2</sub>-Depleting Nano-Assembly Enable In Situ Tumor Depositional Embolization.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39328009.
- Also identified by DOI 10.1002/adhm.202402899.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Abnormal metabolism and blood supply/O<sub>2</sub> imbalance in tumor cells affect drug transport delivery and increase the difficulty of tumor treatment. Controlling tumor growth by inhibiting tumor cell metabolism and regulating progressive embolization in the tumor region provides an innovative basis for constructing tumor therapeutic models. A highly biocompatible and efficient O<sub>2</sub>-depleting agent has been investigated to enable in situ precipitation and embolization within the tumor microenvironment. In situ deformation embolizer, Fe-GA@CaCO<sub>3</sub> nano-assembly (GA: gallic acid), can convert into the large granular size embolization components of Fe(III) precipitates and affluent Ca<sup>2+</sup> within the tumor microenvironment. In situ progressive O<sub>2</sub> depletion produces Fe(III) precipitates that embolize tumor regions, isolating O<sub>2</sub> and nutrients by blocking supply. Meanwhile, affluent Ca<sup>2+</sup> acts on the intracellular, causing mitochondrial dysfunction through calcium overload and contributing to irreversible tumor cell damage. Both internal and external routes work synergistically to produce precise functional inhibition of tumors from the inside out, simultaneously responding to both intracellular and the corresponding tumor regions, providing an innovative solution for anti-tumor therapy.
Medical subject headings
- Oxygen